Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
| Credit Types: | CME |
| Credit Amount: | 0.5 Credits |
| Release Date: | 2011-Oct-05 |
| Expiration Date: | 2012-Oct-04 |
| Estimated Time for Completion: | 30 minutes |
| Registration Required: | No |
| Cost: | Free |
This activity provides an update of recent clinical trial findings in the areas of colorectal cancer, hepatocellular carcinoma, pancreatic neuroendocrine tumors, and pancreatic adenocarcinoma based on data reported at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO). In addition, expert perspectives on the clinical and research implications of the study findings are presented.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of oncologists, advanced practice oncology nurses, and other clinicians involved in the management of patients with gastrointestinal malignancies.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: October 05, 2011 - October 04, 2012
Time to Complete: 30 minutes
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Harold Harvey, MD
Professor of Medicine
Division of Hematology/Oncology
Penn State College of Medicine
Hershey, Pennsylvania
Harold Harvey, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Geron Corporation; Ipsen; and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education
Kathryn B. Charalambous, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Genentech, Inc.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
"OpenCME has initially been made available in a "beta" edition with minimal content, functionality and online presence. Our editorial team is working hard to add many other specialty areas to the list above."
Which of the following may replace 5-fluorouracil in the perioperative treatment of locally advanced rectal cancer?
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high quality CME content by adding the OpenCME Widget to one or more of your pages.